News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altor BioScience Corporation Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801



12/20/2007 9:23:21 AM

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation today announced it has completed treatment of the first cohort of metastatic cancer patients in a Phase I/IIa clinical trial with the Company's lead drug candidate, ALT-801. Altor also reported that the expansion phase of this clinical trial will be supported in part through funding awarded by the U.S. Food and Drug Administration (FDA) Orphan Products Development (OPD) Grant Program. ALT-801 is a novel tumor-targeted immunotherapeutic designed to improve on the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES